Tandem autologous versus autologous/allogeneic transplantation for multiple myeloma: propensity score analysis

被引：6

作者：

Kawamura, Koji ^{[1
]}

Ikeda, Takashi ^{[2
]}

Hagiwara, Shotaro ^{[3
]}

Mori, Takehiko ^{[4
]}

Shinagawa, Atsushi ^{[5
]}

Nishiwaki, Kaichi ^{[6
]}

Ohashi, Kazuteru ^{[7
]}

Kubonishi, Shiro ^{[8
]}

Fukuda, Takahiro ^{[9
]}

Ito, Toshiro ^{[10
]}

Tomita, Naoto ^{[11
]}

Ichinohe, Tatsuo ^{[12
]}

Kato, Koji ^{[13
]}

Morishima, Yasuo ^{[14
]}

Atsuta, Yoshiko ^{[15
,16
]}

Sunami, Kazutaka ^{[8
]}

Kanda, Yoshinobu ^{[1
,17
]}

机构：

[1] Jichi Med Univ, Saitama Med Ctr, Div Hematol, Saitama, Japan

[2] Shizuoka Canc Ctr, Div Hematol & Stem Cell Transplantat, Shizuoka, Japan

[3] Natl Ctr Global Hlth & Med, Div Hematol, Internal Med, Tokyo, Japan

[4] Keio Univ, Div Hematol, Dept Med, Sch Med, Tokyo, Japan

[5] Hitachi Ltd, Hitachi Gen Hosp, Dept Hematol, Hitachi, Japan

[6] Jikei Univ, Sch Med, Kashiwa Hosp, Dept Internal Med,Div Oncol & Hematol, Kashiwa, Chiba, Japan

[7] Komagome Hosp, Tokyo Metropolitan Canc & Infect Dis Ctr, Div Hematol, Tokyo, Japan

[8] Natl Hosp Org Okayama Med Ctr, Dept Hematol, Okayama, Japan

[9] Natl Canc Ctr, Div Hematopoiet Stem Cell Transplantat, Tokyo, Japan

[10] Shinshu Univ, Sch Med, Dept Internal Med 2, Div Hematol, Matsumoto, Nagano, Japan

[11] Yokohama City Univ Med, Dept Rheumatol Hematol Infect Dis, Yokohama, Kanagawa, Japan

[12] Hiroshima Univ, Res Inst Radiat Biol & Med, Dept Hematol & Oncol, Hiroshima, Japan

[13] Japanese Red Cross Nagoya First Hosp, Dept Hematol & Oncol, Childrens Med Ctr, Nagoya, Aichi, Japan

[14] Aichi Canc Ctr, Res Inst, Dept Epidemiol & Prevent, Nagoya, Aichi, Japan

[15] Japanese Data Ctr Hematopoiet Cell Transplantat, Nagoya, Aichi, Japan

[16] Nagoya Univ, Dept Healthcare Adm, Grad Sch Med, Nagoya, Aichi, Japan

[17] Jichi Med Univ, Div Hematol, Dept Med, Shimotsuke, Japan

来源：

LEUKEMIA & LYMPHOMA | 2016年 / 57卷 / 09期

关键词：

Allogeneic transplantation; multiple myeloma; novel agents; propensity score analysis; tandem autologous transplantation; STEM-CELL TRANSPLANTATION; TERM-FOLLOW-UP; LENALIDOMIDE PLUS DEXAMETHASONE; NEWLY-DIAGNOSED MYELOMA; RISK; TRIAL; MAINTENANCE; IFM99-03;

D O I：

10.3109/10428194.2016.1154958

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Autologous hematopoietic stem cell transplantation (auto-HCT) is considered a standard therapy for transplant-eligible patients with multiple myeloma, while allogeneic HCT (allo-HCT) is controversial. We retrospectively analyzed 765 patients with myeloma who underwent tandem transplantation between 1998 and 2012 using Japanese registry data. We evaluated the clinical outcomes of tandem auto-HCT (n=676) and auto/allo-HCT (n=89). To adjust for a selection bias, we compared overall survival (OS) between the two groups by a propensity score analysis. The probability of OS at six years was 58.5% for the tandem auto-HCT group and 54.4% for the tandem auto/allo-HCT group (p=0.47). In a matched-pair analysis based on the propensity score, the difference in survival between the two groups was not statistically significant, although the survival curve appeared to reach a plateau beyond five years in the auto/allo group. Further strategies to reduce treatment-related mortality and enhance a graft-versus-myeloma effect are necessary to improve OS.

引用

页码：2077 / 2083

页数：7

共 29 条

[1] Lenalidomide Maintenance for High-Risk Multiple Myeloma after Allogeneic Hematopoietic Cell Transplantation [J].

Alsina, Melissa ;

Becker, Pamela S. ;

Zhong, Xiaobo ;

Adams, Alexia ;

Hari, Parameswaran ;

Rowley, Scott ;

Stadtmauer, Edward A. ;

Vesole, David H. ;

Logan, Brent ;

Weisdorf, Daniel ;

Qazilbash, Muzaffar ;

Popplewell, Leslie L. ;

McClune, Brian ;

Bensinger, William ;

Riches, Marcie ;

Giralt, Sergio A. ;

Pasquini, Marcelo C. .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2014, 20 (08) :1183-1189

[2] Tandem autologous vs autologous plus reduced intensity allogeneic transplantation in the upfront management of multiple myeloma: meta-analysis of trials with biological assignment [J].

Armeson, K. E. ;

Hill, E. G. ;

Costa, L. J. .

BONE MARROW TRANSPLANTATION, 2013, 48 (04) :562-567

[3] Unification of hematopoietic stem cell transplantation registries in Japan and establishment of the TRUMP system [J].

Atsuta, Yoshiko ;

Suzuki, Ritsuro ;

Yoshimi, Ayami ;

Gondo, Hisashi ;

Tanaka, Junji ;

Hiraoka, Akira ;

Kato, Koji ;

Tabuchi, Ken ;

Tsuchida, Masahiro ;

Morishima, Yasuo ;

Mitamura, Makoto ;

Kawa, Keisei ;

Kato, Shunichi ;

Nagamura, Tokiko ;

Takanashi, Minoko ;

Kodera, Yoshihisa .

INTERNATIONAL JOURNAL OF HEMATOLOGY, 2007, 86 (03) :269-274

[4] Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma [J].

Attal, Michel ;

Lauwers-Cances, Valerie ;

Marit, Gerald ;

Caillot, Denis ;

Moreau, Philippe ;

Facon, Thierry ;

Stoppa, Anne Marie ;

Hulin, Cyrille ;

Benboubker, Lofti ;

Garderet, Laurent ;

Decaux, Olivier ;

Leyvraz, Serge ;

Vekemans, Marie-Christiane ;

Voillat, Laurent ;

Michallet, Mauricette ;

Pegourie, Brigitte ;

Dumontet, Charles ;

Roussel, Murielle ;

Leleu, Xavier ;

Mathiot, Claire ;

Payen, Catherine ;

Avet-Loiseau, Herve ;

Harousseau, Jean-Luc .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (19) :1782-1791

[5] Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: Final results of phase III US intergroup trial S9321 [J].

Barlogie, B ;

Kyle, RA ;

Anderson, KC ;

Greipp, PR ;

Lazarus, HM ;

Hurd, DD ;

McCoy, J ;

Dakhil, SR ;

Lanier, KS ;

Chapman, RA ;

Cromer, JN ;

Salmon, SE ;

Durie, B ;

Crowley, JC .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (06) :929-936

[6] Tandem Autologous/Reduced-Intensity Conditioning Allogeneic Stem-Cell Transplantation Versus Autologous Transplantation in Myeloma: Long-Term Follow-Up [J].

Bjorkstrand, Bo ;

Iacobelli, Simona ;

Hegenbart, Ute ;

Gruber, Astrid ;

Greinix, Hildegard ;

Volin, Liisa ;

Narni, Franco ;

Musto, Pellegrino ;

Beksac, Meral ;

Bosi, Alberto ;

Milone, Giuseppe ;

Corradini, Paolo ;

Goldschmidt, Hartmut ;

de Witte, Theo ;

Morris, Curly ;

Niederwieser, Dietger ;

Gahrton, Gosta .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (22) :3016-3022

[7]

Blade Joan, 1998, British Journal of Haematology, V102, P1115, DOI 10.1046/j.1365-2141.1998.00930.x

[8] A comparison of allografting with autografting for newly diagnosed myeloma [J].

Bruno, Benedetto ;

Rotta, Marcello ;

Patriarca, Francesca ;

Mordini, Nicola ;

Allione, Bernardino ;

Carnevale-Schianca, Fabrizio ;

Giaccone, Luisa ;

Sorasio, Roberto ;

Omede, Paola ;

Baldi, Ileana ;

Bringhen, Sara ;

Massaia, Massimo ;

Aglietta, Massimo ;

Levis, Alessandro ;

Gallamini, Andrea ;

Fanin, Renato ;

Palumbo, Antonio ;

Storb, Rainer ;

Ciccone, Giovannino ;

Boccadoro, Mario .

NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (11) :1110-1120

[9] Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma [J].

Dimopoulos, Meletios ;

Spencer, Andrew ;

Attal, Michael ;

Prince, H. Miles ;

Harousseau, Jean-Luc ;

Dmoszynska, Anna ;

San Miguel, Jesus ;

Hellmann, Andrzej ;

Facon, Thierry ;

Foa, Robin ;

Corso, Alessandro ;

Masliak, Zvenyslava ;

Olesnyckyj, Marta ;

Yu, Zhinuan ;

Patin, John ;

Zeldis, Jerome B. ;

Knight, Robert D. .

NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (21) :2123-2132

[10] A proportional hazards model for the subdistribution of a competing risk [J].

Fine, JP ;

Gray, RJ .

JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1999, 94 (446) :496-509

← 1 2 3 →